Background: Obesity is a serious health problem that dysregulate Renin-Angiotensin System (RAS) and intestinal microbiota.

Objective: The present study aimed to evaluate the Angiotensin-(1-7) [ANG-(1-7)] oral formulation effects on obese mice intestinal microbiota.

Methods: Mice were divided into four groups: obese and non-obese treated with ANG-(1-7) and obese and non-obese without ANG-(1-7) during four weeks.

Results: We observed a significant decrease in the fasting plasma glucose, total cholesterol, triglycerides, and Low-density lipoprotein levels and increased High-density lipoprotein in animals treated with ANG-(1-7). The histological analysis showed intestinal villi height reduction in mice treated with ANG-(1-7). Additionally, increased Bacteroidetes and decreased Firmicutes (increased Bacteroidetes/ Firmicutes ratio) and Enterobacter cloacae populations were observed in the High-Fat Diet + ANG-(1-7) group. Receptor toll-like 4 (TLR4) intestinal mRNA expression was reduced in the HFD+ANG-(1-7) group. Finally, the intestinal expression of the neutral amino acid transporter (B0AT1) was increased in animals treated with ANG-(1-7), indicating a possible mechanism associated with tryptophan uptake.

Conclusion: The results of the present study suggest for the first time an interaction between oral ANG-(1-7) and intestinal microbiota modulation.

背景：肥胖是一种严重的健康问题，会导致肾素-血管紧张素系统 (RAS) 和肠道微生物群失调。

目的：本研究旨在评估血管紧张素-(1-7) [ANG-(1-7)] 口服制剂对肥胖小鼠肠道菌群的影响。

方法：将小鼠分为四组：用 ANG-(1-7) 治疗的肥胖和非肥胖以及在 4 周内不使用 ANG-(1-7) 的肥胖和非肥胖。

结果：我们观察到用 ANG-(1-7) 治疗的动物的空腹血糖、总胆固醇、甘油三酯和低密度脂蛋白水平显着降低，高密度脂蛋白水平升高。组织学分析显示用 ANG-(1-7) 治疗的小鼠的肠绒毛高度降低。此外，在高脂饮食 + ANG-(1-7) 组中观察到拟杆菌门增加和厚壁菌门减少（拟杆菌门/厚壁菌门比率增加）和阴沟肠杆菌群。HFD+ANG-(1-7) 组的受体 toll 样 4 (TLR4) 肠道 mRNA 表达降低。最后，在用 ANG-(1-7) 治疗的动物中，中性氨基酸转运蛋白 (B0AT1) 的肠道表达增加，表明可能存在与色氨酸摄取相关的机制。

结论：本研究的结果首次表明口服 ANG-(1-7) 与肠道微生物群调节之间存在相互作用。